Eli Lilly Reports 62% Response Rate for Olomorasib Combination in First-Line NSCLC
Eli Lilly reported a 62% response rate for investigational olomorasib in combination therapy for first-line KRAS G12C-mutant non-small cell lung cancer.
Eli Lilly reported a 62% response rate for investigational olomorasib in combination therapy for first-line KRAS G12C-mutant non-small cell lung cancer.